¡¡

HOME > Resources > Newsletters

¡¡

Title

The number of Madrid international trademark applications filed by the Republic of Korea decreased while that filed by the competing countries increased (160)

Author¡¡

KH

Post Date¡¡

2009-01-16

Read

11054

Attach File

-
1. The number of Madrid international trademark applications filed by the Republic of Korea decreased while that filed by the competing countries increased

The number of the applications filed by the Republic of Korea in 2008, using the Madrid international trademark application system, decreased, while the number of the applications filed by the major competing countries increased. According to a report dated December 16, 2008 from the Korean Intellectual Property Office (KIPO; Commissioner: Jung-sik KOH), as a result of estimating the number of applications to be filed by the end of 2008 based on the statistics up to November 2008, the number of Madrid international trademark applications filed by Korean applicants is expected to be 218 (based on 204 as of November), which is considerably less than 283 in 2007.

This is a decrease of 23.0% compared to the number filed in 2007, and this decrease is in contrast to the increases of 35.0% in 2006 and 36.1% in 2007.

However, the number of Madrid international trademark applications which are filed in the Republic of Korea by foreign applicants from major countries including Germany, US, France and China, among others, is expected to be 9,863 in 2008 (based on 8,794 as of November), with an increase of 8.7%, compared to 9,072 in 2007.

Classified by countries, Germany has the most trademark applications with 5,037, followed by US with 4,738, France with 2,943, Switzerland with 2,606, China with 2,526, and Japan with 2,193.

¡°In spite of the advantages of the Madrid international trademark application system, the number of the applications filed by the Republic of Korea has been at a standstill for some years, compared to the major competing countries. KIPO will positively support activities, for example, examiners will directly visit medium and small companies to present strategies to obtain international trademark rights using the Madrid system,¡± said a KIPO spokesman.


2. The number of patent applications filed by universities is rapidly increasing

The number of patent applications filed by universities in 2007 greatly increased. According to the 2007 University-Industry Cooperation White Paper, published by the Ministry of Education, Science and Technology and the Korea Research Foundation on December 11, 2008, the number of Korean patent applications filed by universities in 2007 was 7,326 and the number of foreign patent application filed by universities in 2007 was 787, increasing by 58.1% and 7.7% respectively, compared to the numbers in 2006.

The number of Korean patents being registered was 4,052 with an increase of 36.3%, and the number of foreign patents being registered was 213 with an increase of 16.4%.

The number of patent applications per billion Korea Won for research expenses for science and technology was 2.9, with an increase compared to 2.5 in 2006. Therefore, productivity is considered to have slightly increased.

The number of technology transfer agreements of companies is 951, with an increase of 68.9%. The revenues by the technology transfer are totaled as 16,415,000,000 Korea Won.

Classified by the fields of technology transfer, the field of information technology (IT) has the most technical transfer cases with 313, followed by the field of bio-technology with 226. Classified by the types of technology transfer, the technology transfer of patents is 46.1% and that of know-how is 46.0%, among others.


3. Seventeen medical ingredients of which the patents are confirmed to expire in 2010 are published

There are published the first patent information of 17 medical ingredients which are the substance patents to expire in 2010.

On December 10, 2008, the Korea Health Industry Development Institute (KHIDI, President: Bup-wan KIM) announced that they published, jointly with KIPO, the ¡®information and analysis on substance patents having patent terms which will expire in 2010, and a study on strategies using those substance patents¡¯ at the patent information website, http://patent.khidi.or.kr.

According to the aforementioned publication, among a total of 138 substance patents having their patent terms to expire in 2010, 51.4% (71 patents) is in the medical drug field, 20.3% (28 patents) is in the biotech field, 15.9% (22 patents) is in the agricultural chemical field, 4.3% (6 patents) is in the plastic field, and the remaining patents (11 patents) are in other industrial fields.

Specifically, this publication includes 17 substance patents in the field of medical drugs, the ingredients of which are verified by the FDA Orange Book, among others, in the USA. Further, this publication includes the detailed results of analyzing the total available information, such as product information regarding the 26 medical substance patents. Therefore, drug companies are expected to use those substance patents.

According to KHIDI, among the substance patents having verified ingredients in the field of medical drugs, the overseas market of the 17 substances, such as ¡°amlodipine besylate salt¡±, among others, has reached about 150,000,000,000 to 3,500,000,000 Korea Won, and the Korean market thereof indicated about 209,000,000,000 to 785,000,000,000 Korea Won in 2007.

The published substance patents specifically include the following substances, among others:
- amlodipine besylate salt (substance name: amlodipine; use: treatment for high blood pressure; development company: Pfizer)
- taxol derivatives, their preparation and pharmaceutical compositions containing them (substance name: docetaxel; use: treatment for non-small cell lung cancer, breast cancer, and the like; development company: Rhone-Poulenc Rorer Inc.)
- crystalline carbapenem compounds, their preparation and use (substance name: meropenem; use: septicemia, superficial purulent disease, and the like; development company: Sumitomo Pharmaceuticals

Pfizer filed the application of the invention for ¡®amlodipine besylate salt¡¯ on August 5, 1987, which was registered on October 30, 1995.

The substance according to this invention was developed as a brand name, for example, ¡°Norvasc¡± for treatment of high blood pressure by Pfizer. According to KHIDI, Pfizer Korea introduced the substance at home and recorded the actual sale results of about 785,000,000,000 Korea Won in 2008

The patent term of the substance patent according to this invention will expire on July 7, 2010.


4. Korean Electron and Telecommunication Research Institute (ETRI) developed the first ¡®u-robot server middleware¡¯ in the world

A Korean research team developed the first technology of easily developing and using various intelligent robot application services based on the network.

On December 22, 2008, ETRI announced that they developed the ¡®u-robot server middleware (CAMUS: Context-Awareness Middleware for URC Systems) technology¡¯ which is a standard platform to support the u-robot to be actively and intellectually aware of context, based on the network in the home environment, u-City environment, or the like.

This technology stably provides a number of different robots with various high-performance services which is difficult to provide in a robot itself, in operatively connection with a home network system or other servers through a high-speed communication infra-net, such as an existing optical network.

Various robot platforms are capable of improving the active and intellectual application services, such as voice-aware services, image-aware services, context-aware services, in the environment operatively connected to a robot server, through different kinds of communication nets.

Then, the u-robot acquires and interprets a diversity of context information and performs an important function to perform the service based on the interpreted results.

A user can remotely monitor or control, in real-time, the operating robot at home or office environment, using various mobile devic ¡¡

Prev¡¡

Reasons for changing official fees from January 1, 2009 (161)

Next¡¡

A ¡°remote-consultation system regarding the filing of a patent application¡± is established for the first time in the world (159)
¡¡ ¡¡ ¡¡ ¡¡ ¡¡ ¡¡ ¡¡
¡¡ ¡¡ ¡¡ ¡¡ ¡¡ ¡¡

¡¡

¡¡ ¡¡ ¡¡ ¡¡ ¡¡ ¡¡ ¡¡
¡¡
¡¡